Redcliffe Labs to invest $10mn towards genetic, specialised testing portfolio expansion

New Delhi: Redcliffe Labs plans to invest further $10 mn towards the expansion of its genetic and specialised testing portfolio.

The company has invested $6mn earlier into genetics and specialised testing coverage from prenatal to oncology, neurology, nephrology, gut microbiome and the fastest-growing pharmacogenomics.

“We plan to add advanced high throughput NGS facilities at our expanded NRL site and de-centralised low throughput sequencers across all regional reference labs. This will bring the fastest TAT to our clinicians and truly build affordable genomics. The technology choices are governed by main factors like reducing sequencing cost and innovation led by market leaders like Illumina, ThermoFisher, Oxford Nanapore, etc,” says Dheeraj Jain, Founder & MD, Redcliffe Labs.

The company at present has 43+ labs and 1100+ authorised collection centres, and it is working towards building additional 57 labs in the next six months, 1200 collection centres, and be accessible in more than 200 cities and 3500 pin-codes by June’23.